Business Wire

The Latest RoboSense LiDAR Perception Solution Will Support Robo Taxi Development

4.12.2019 17:00:00 EET | Business Wire | Press release

Share

RoboSense today announced its launch of a developed and complete LiDAR perception solution for Robo Taxi (RS-Fusion-P5) in markets outside China. The RS-Fusion-P5 was first launched in China last month. Equipped with an RS-Ruby and four RS-BPearl, The RS-Fusion-P5 is considered to be the alternative to Waymo's LiDAR solution, further accelerating the development of Robo Taxi.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191204005271/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Graphic: Business Wire)

Full Coverage, Zero Blind Spots In The Range Of 200 Meters

RoboSense RS-Fusion-P5 uses an RS-Ruby on top of the vehicle to ensure a sensing range with a radius of more than 200 meters. However, even if the vertical field of view (FOV) of RS-Ruby reaches the perfect angles from -25° to +15°, there is still a small blind zone around the vehicle body. Therefore, to cover the small blind zone, 4 RS-BPearl embedded sideways around the vehicle form a hemisphere FOV scanning area relative to the vehicle's perspective, to guarantee a complete 360° surrounding view.

Empowers Level 4 Or Above Autonomous Vehicles With Full-stack Perception Capabilities

The RS-Fusion-P5 solution fuses point clouds from RS-Ruby and RS-BPearl in real-time, and generate laser points of more than 4,600,000pts per second.

Through its advanced AI perception algorithms, multi-sensor fusion and synchronization interfaces, vehicles are able to identify all-around obstacles and position easily and precisely.

The Main RS-Ruby With 0.1 ° Vertical Resolution, 200m @ 10% Ranging Ability

RS-Ruby achieves the anti-interference of multiple LiDAR using special laser encryption technology to filter interference signals. Meanwhile, it is not affected by the strongest direct-sunlight. Its LiDAR reflection intensity reaches a perfect balance of consistency and distinction.

RS-BPearl Reaches The Minimum Detection Range Of Less Than 5cm

The embedded four RS-BPearl form a hemispherical FOV coverage of 90 ° * 360 °, which not only can precisely identify objects around the vehicle body such as pets, children, roadbeds as well as other details of the near-field ground area, but also detect the actual height information under particular scenarios such as bridge tunnels and culverts, further supporting autonomous vehicles for driving decision making and greatly improving car safety.

The RS-Fusion-P5 is able to reach 200m detection range, 0.1° high-precision resolution with full coverage, zero blind spots in the sensing zone. It is one of the leading and developed automotive LiDAR solution for Robo Taxi available on the market. More details of RS-Fusion-P5 can be found at http://www.robosense.cn/rslidar/rs-fusion-p5.

Meanwhile, RoboSense wins CES 2020 Innovation Award for autonomous vehicle technology, and will be exhibiting at booth 6138, LVCC North Hall, CES 2020 from Jan. 7 – 10, 2020, and tabletop No. 602 at CES Unveiled Las Vegas, on Jan. 5, 2020, 5 – 8:30 p.m. PST.

About RoboSense:
The world’s leading autonomous driving LiDAR perception solution provider, RoboSense, supplies LiDAR technologies to a wide range of domestic and international autonomous driving technology companies, OEMs, and tier 1 suppliers. RoboSense technologies are widely used in autonomous driving logistics vehicles, buses, and passenger cars, with partners including SAIC, BAIC, Baidu, Cainiao Network, JD.com, ControlWorks, Aidrivers, and more. In China, RoboSense has received more than 300 million RMB in strategic investments from Alibaba’s Cainiao Network, SAIC, and BAIC, making RoboSense Asia’s number one LiDAR company, with the largest funding in China’s LiDAR industry. RoboSense has won numerous international awards, including the CES 2020 and 2019 Innovation Awards, the 2019 AutoSens Award, and the 2019 Stevie Award - Gold Award. For more information on RoboSense, see the website at http://www.robosense.ai.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Cassie Gong
RoboSense PR Manager
sqgong@robosense.cn
86-18620031448

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye